<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499291</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000554709</org_study_id>
    <secondary_id>ECOG-E1Y06</secondary_id>
    <nct_id>NCT00499291</nct_id>
  </id_info>
  <brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors</brief_title>
  <official_title>Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
      formulation, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing.

      PURPOSE: This clinical trial is studying how well paclitaxel albumin-stabilized nanoparticle
      formulation works in treating patients with advanced or refractory solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To develop a population pharmacokinetic model for paclitaxel administered as paclitaxel
           albumin-stabilized nanoparticle formulation (nab-paclitaxel) to a large population of
           patients with advanced or refractory cancer to characterize the inter-individual
           pharmacokinetic variability of this agent.

      Secondary

        -  To explore nab-paclitaxel pharmacokinetic parameters in patients with metastatic
           prostate cancer (castrate), metastatic breast cancer, advanced non-small cell lung
           cancer and other incurable advanced or refractory tumors amenable to treatment with
           nab-paclitaxel.

        -  To explore the association between exposure to total and unbound paclitaxel after
           administration of nab-paclitaxel and neutropenia.

        -  To explore the association between the CYP2C8*3 variant and paclitaxel clearance.

        -  To explore the association between other variants of CYP2C8 and other genes involved in
           paclitaxel disposition including CYP3A4, CYP3A5, SLCO1B3 (OATP8), and ABCB1 (MDR1) and
           paclitaxel pharmacokinetic parameters and toxicity after one course of treatment.

      OUTLINE: This is a multicenter study.

      Patients receive paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) IV
      over 30 minutes on days 1, 8, 15, 22, 29, 36, 43, and 50. Treatment may repeat off study
      every 9 weeks in the absence of disease progression or unacceptable toxicity.

      Serial blood samplings are obtained at specified time points during course 1 including
      baseline and days 1 and 8 of course 1 for pharmacokinetic studies. Samples are also examined
      for genotype by PCR including variant genotypes in 2C8, CYP3A4, CYP3A5, ABCB1, ABCC2, ABCC10
      and OATP1B3 genes.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Anticipated">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inter-individual pharmacokinetic variability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutropenia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYP2C8*3 variant expression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic variance relating to pharmacokinetics and toxicity</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patients must have an incurable advanced or refractory tumor amenable to treatment
             with paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)

               -  Per the National Comprehensive Cancer Network, the following cancer sites have
                  been shown to be responsive to taxane therapy:

                    -  Prostate cancer

                    -  Breast cancer

                    -  Non-small cell lung cancer

                    -  Bladder cancer

                    -  Head and neck cancer

                    -  Oral cancer

                    -  Cervical cancer

                    -  Ovarian cancer

                    -  Endometrial cancer

                    -  Esophageal cancer

                    -  Gastric cancer

                    -  Germ cell tumors

                    -  Tumors of unknown primary

                    -  Soft tissue sarcomas

                    -  Small cell lung cancer

                    -  Testicular cancer

                    -  Upper genitourinary tract cancers

        PATIENT CHARACTERISTICS:

          -  Patients must have performance status 0-2 by the ECOG scale

          -  Absolute neutrophil count ≥ 1,500/μL

          -  Platelet count ≥ 100,000/μL

          -  Hemoglobin ≥ 9 g/dL

          -  Bilirubin ≤ institutional upper limit of normal (ULN)

          -  ALT and AST ≤ 2.5 x ULN

          -  Alkaline phosphatase ≤ 2.5 x ULN (if bone metastasis is present in the absence of
             liver metastasis, alkaline phosphatase must be ≤ 5 x ULN)

          -  Creatinine ≤ 1.5 x ULN

          -  Patients must not have baseline sensory neuropathy ≥ grade 2

          -  Women must not be pregnant or breastfeeding

          -  Negative blood or urine pregnancy test

          -  Women of childbearing potential and sexually active males must agree to use an
             accepted and effective method of contraception

        PRIOR CONCURRENT THERAPY:

          -  Prior treatment is allowed, which may include prior taxane therapy

               -  If patient has had prior therapy(ies), s/he must have received last treatment ≥
                  28 days prior to registration

          -  Patients must not be receiving colony stimulating factors (CSFs)

               -  Previous CSFs must have been discontinued &gt; 14 days prior to registration

          -  Patients must not be receiving concomitant treatment with any of the following (prior
             use is allowed, but must have been discontinued ≥ 28 days prior to registration):

               -  Phenytoin

               -  Carbamazepine

               -  Barbiturates

               -  Rifampicin

               -  Phenobarbital

               -  Hypericum perforatum (St. John's wort)

               -  Ketoconazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sridhar Mani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>clear cell sarcoma of the kidney</keyword>
  <keyword>rhabdoid tumor of the kidney</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage III ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent hypopharyngeal cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage IV hypopharyngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage IV laryngeal cancer</keyword>
  <keyword>recurrent lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage IV lip and oral cavity cancer</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>recurrent oropharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>recurrent paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage IV paranasal sinus and nasal cavity cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult teratoma</keyword>
  <keyword>ovarian teratoma</keyword>
  <keyword>testicular teratoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

